RAPT (RAPT Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

RAPT (RAPT Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

RAPTRAPT Therapeutics, Inc.

Mkt Cap$959M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$106M

EPS (TTM)-$11.07

Free Cash Flow (TTM)-$87M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$24M
Q1 23	$0	$0	-$32M
Q2 23	$0	$0	-$28M
Q3 23	$0	$0	-$34M
Q4 23	$0	$0	-$33M
Q1 24	$0	-$314K	-$33M
Q2 24	$0	$0	-$29M
Q3 24	$0	$0	-$20M
Q4 24	$0	$0	-$54M
Q1 25	$0	$0	-$19M
Q2 25	$0	-$200K	-$20M
Q3 25	$0	$0	-$19M

Valuation

Quarter	P/S	P/E
Q4 22	628.2x	—
Q1 23	1082.7x	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$23M	-$23M
Q1 23	-$19M	-$19M
Q2 23	-$29M	-$29M
Q3 23	-$22M	-$22M
Q4 23	-$28M	-$28M
Q1 24	-$27M	-$27M
Q2 24	-$28M	-$28M
Q3 24	-$18M	-$18M
Q4 24	-$10M	-$10M
Q1 25	-$52M	-$52M
Q2 25	-$11M	-$11M
Q3 25	-$12M	-$12M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$49K
Q1 23	$759K
Q2 23	$233K
Q3 23	$66K
Q4 23	$67K
Q1 24	$105K
Q2 24	$1K
Q3 24	$17K
Q4 24	$1K
Q1 25	$43K
Q2 25	$40K
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-100.0%	+30.0%
Q1 23	-100.0%	+47.4%
Q2 23	-100.0%	+43.3%
Q3 23	—	+56.5%
Q4 23	—	+36.0%
Q1 24	—	+3.0%
Q2 24	—	+3.4%
Q3 24	—	-41.7%
Q4 24	—	+64.0%
Q1 25	—	-40.8%
Q2 25	—	-33.4%
Q3 25	—	-2.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$3M	—
Q1 23	$0	—
Q2 23	$4M	—
Q3 23	$0	—
Q4 23	$4M	—
Q1 24	$5M	—
Q2 24	$5M	—
Q3 24	$5M	—
Q4 24	$5M	—
Q1 25	$5M	—
Q2 25	$5M	—
Q3 25	$5M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$19M	$5M
Q1 23	$26M	$6M
Q2 23	$22M	$7M
Q3 23	$27M	$7M
Q4 23	$27M	$6M
Q1 24	$25M	$8M
Q2 24	$23M	$7M
Q3 24	$13M	$6M
Q4 24	$46M	$8M
Q1 25	$12M	$7M
Q2 25	$12M	$7M
Q3 25	$12M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$39M	$210M	$249M
Q1 23	$46M	$186M	$232M
Q2 23	$50M	$155M	$205M
Q3 23	$54M	$131M	$185M
Q4 23	$47M	$111M	$159M
Q1 24	$45M	$96M	$142M
Q2 24	$37M	$78M	$115M
Q3 24	$38M	$60M	$98M
Q4 24	$170M	$61M	$231M
Q1 25	$60M	$119M	$179M
Q2 25	$42M	$127M	$169M
Q3 25	$38M	$119M	$157M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	4M	+6.0%
Q1 23	5M	+7.3%
Q2 23	5M	+0.1%
Q3 23	5M	+0.1%
Q4 23	5M	+0.1%
Q1 24	5M	+0.6%
Q2 24	5M	+0.6%
Q3 24	5M	+0.1%
Q4 24	6M	+20.0%
Q1 25	27M	+361.4%
Q2 25	27M	+0.1%
Q3 25	27M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 17	—	—
FY 18	—	—
FY 19	$0	67
FY 20	$74K	68
FY 21	$47K	81
FY 22	$16K	97
FY 23	$0	131
FY 24	$0	68